PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10147431

Current transfusion therapy: indications for basic components.

E F Williams
View original source ↗Export metadata ↓

Abstract

OBJECTIVE: To review basic blood components and currently acceptable transfusion practices. DATA SOURCES: Professional journals, current texts, and the author's experience. STUDY SELECTION: Not applicable. DATA EXTRACTION: Not applicable. DATA SYNTHESIS: Red blood cells, platelets, cryoprecipitate, and fresh-frozen plasma are the basic blood components ordered daily in hospitals and transfusion services all over the world. To notify the laboratory medical director of inappropriate orders for components, the clinical laboratory scientist must be aware of currently acceptable transfusion practices. This article reviews these four components and indicates acceptable processing methods and appropriate use. CONCLUSION: Considering the known risk factors of blood and blood component transfusions, it is essential that components be used only when necessary. Criteria for appropriate transfusion have changed over the years; old transfusion triggers are no longer acceptable. To provide the best medical care to the patient, the clinical laboratory scientist must stay abreast of currently acceptable transfusion practices.

Explore related subjects

Blood Component TransfusionBlood PlateletsHumansPlasmaPractice Guidelines as TopicJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E F Williams. Current transfusion therapy: indications for basic components.. https://pubmed.ncbi.nlm.nih.gov/10147431/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

[Hepatitis after blood transfusion in inpatients. Post-transfusion hepatitis, or infection of other etiology?].

BACKGROUND AND OBJECTIVE: Hepatitis after a transfusion of blood products is often uncritically called post-transfusion hepatitis (PTH). It was the aim of this study to ascertain in how many reported cases of suspected PTH a causal relationship between transfusion and the infection in the recipient can be proven. PATIENTS AND METHODS: Full investigations (look-back method) were made of 23 cases of PTH reported in the 10-year period of 1987-1997 (11 cases of PTH B and 12 of PTH non-A-non-B or C). The recipients had been given a mean of 7.7 blood components (range 1-57). The clinical diagnosis had been made a mean of 5.2 (range 1-27) months after transfusion. RESULTS: One case each of hepatitis B and C had been caused by transfusion of blood products. In 5 of 12 suspected cases of PTH non-A-non-B hepatitis C, PTH could not be definitively excluded (despite absent seroconversion for anti-hepatitis C virus [HCV]), because HCV-RNA findings were not available. In 16 of 23 investigated cases serological and molecular-biological tests firmly excluded PTH B or C. CONCLUSIONS: The small number of confirmed cases of PTH indicates that hepatitis that has occurred post-transfusion is frequently due to a cause not related to the transfusion. The number of transfusion-associated cases will be further reduced with the introduction (standard since 1.4.1999) of VCH-RNA screening of donors. This will raise the importance of hepatitis cases not associated with transfusion.

Blood Component Transfusion↗
PubMed2000

Camouflaged blood cells: low-technology bioengineering for transfusion medicine?

The small number of studies done on the covalent modification of RBC with PEG, or PEG-derivatives, suggests that the immunocamouflage of intact cells significantly reduces the antigenicity and immunogenicity of the foreign cell. Importantly, this protective immunologic effect can be accomplished without adversely affecting the structure, function, or viability of the modified cell (e.g., RBCs and lymphocytes). As a consequence, PEG-RBC may have significant practical value in the treatment of the chronically transfused patient as a prophylactic measure against allosensitization. The PEG-RBC also may be useful in treating the already allosensitized individual. As shown, preexisting antibodies do not effectively recognize nor bind to the modified donor cells. A finding of further interest to transfusion medicine is that pegylation of contaminating lymphocytes within RBC products may prove efficacious in preventing graft-versus-host disease in the immunocompromised patient. However, the main emphasis of our research continues to be the immunocamouflage of RBC for use in chronic transfusion therapy of the SCD and thalassemic patient.

Blood Component Transfusion↗